SAROJVADHANSAROJ VADHAN8440VADHAN, SAROJProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1515 Holcombe Blvd.Houston77030TXAuthorship 1633671Authorship 1634161Authorship 1636353Authorship 1637531Authorship 163784Authorship 1639472Authorship 1641651Authorship 1643111Authorship 1645773Authorship 1645871Authorship 1652611Authorship 1654431Authorship 1655042Authorship 1656614Authorship 1657362Authorship 1657382Authorship 1660916Authorship 1669831Authorship 1671373Authorship 1672626Authorship 1672972Authorship 1693723Authorship 1695133Authorship 1703188Authorship 1739511Authorship 17559215Authorship 1758465Authorship 1761967Authorship 1762583Authorship 1855231Authorship 1927671Authorship 19630111504150Vadhan-Raj SImmunology seriesClinical trials of granulocyte-macrophage colony-stimulating factor for the treatment of aplastic anemia. Immunol Ser. 1992; 57:661-70.Immunol Ser1992-01-01T00:00:001992Clinical trials of granulocyte-macrophage colony-stimulating factor for the treatment of aplastic anemia.1634916Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, Cooper S, Buescher ES, Frenck RW, Holian AJournal of clinical oncology : official journal of the American Society of Clinical OncologyAbrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol. 1992 Aug; 10(8):1266-77.J Clin Oncol1992-08-01T00:00:001992Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.2125781Ventura GJ, Reading CL, Hester JP, Vadhan-Raj SActa haematologicaCirculating myeloid progenitor cell kinetics during hematologic recovery from chemotherapy and subsequent recombinant human granulocyte-macrophage colony-stimulating factor administration. Acta Haematol. 1990; 84(4):175-81.Acta Haematol1990-01-01T00:00:001990Circulating myeloid progenitor cell kinetics during hematologic recovery from chemotherapy and subsequent recombinant human granulocyte-macrophage colony-stimulating factor administration.2467646Vadhan-Raj S, Kellagher MJ, Keating M, Walters R, Gutterman JUBehring Institute MitteilungenPhase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with bone marrow failure and malignancy. Behring Inst Mitt. 1988 Aug; (83):119-24.Behring Inst Mitt1988-08-01T00:00:001988Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with bone marrow failure and malignancy.2549492Frenck RW, Buescher ES, Vadhan-Raj SPediatric researchThe effects of recombinant human granulocyte-macrophage colony stimulating factor on in vitro cord blood granulocyte function. Pediatr Res. 1989 Jul; 26(1):43-8.Pediatr Res1989-07-01T00:00:001989The effects of recombinant human granulocyte-macrophage colony stimulating factor on in vitro cord blood granulocyte function.2643518Ventura GJ, Hester JP, Swan F, Vadhan-Raj S, Turpin J, Dicke KA, Reading CLExperimental hematologyAnalysis of peripheral blood granulocyte-macrophage colony growth by limiting dilution assay. Exp Hematol. 1989 Feb; 17(2):125-9.Exp Hematol1989-02-01T00:00:001989Analysis of peripheral blood granulocyte-macrophage colony growth by limiting dilution assay.2664033Broxmeyer HE, Vadhan-Raj SImmunologic researchPreclinical and clinical studies with the hematopoietic colony-stimulating factors and related interleukins. Immunol Res. 1989; 8(3):185-201.Immunol Res1989-01-01T00:00:001989Preclinical and clinical studies with the hematopoietic colony-stimulating factors and related interleukins.3081247Krown SE, Real FX, Vadhan-Raj S, Cunningham-Rundles S, Krim M, Wong G, Oettgen HFCancerKaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer. 1986 Apr 15; 57(8 Suppl):1662-5.Cancer1986-04-15T00:00:001986Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors.3085930Vadhan-Raj S, Nathan CF, Sherwin SA, Oettgen HF, Krown SECancer treatment reportsPhase I trial of recombinant interferon gamma by 1-hour i.v. infusion. Cancer Treat Rep. 1986 May; 70(5):609-14.Cancer Treat Rep1986-05-01T00:00:001986Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion.3130750Pelus LM, Vadhan-Raj SAmerican journal of hematologyModulation of responsiveness of chronic myelogenous leukemia granulocyte-macrophage colony-forming cells to growth regulation following in vivo treatment with recombinant gamma-interferon. Am J Hematol. 1988 May; 28(1):21-6.Am J Hematol1988-05-01T00:00:001988Modulation of responsiveness of chronic myelogenous leukemia granulocyte-macrophage colony-forming cells to growth regulation following in vivo treatment with recombinant gamma-interferon.3171629Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton ANJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol. 1988 Oct; 6(10):1636-48.J Clin Oncol1988-10-01T00:00:001988Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.3288869The New England journal of medicineGranulocyte-macrophage colony-stimulating factor and myelodysplastic syndromes. N Engl J Med. 1988 Jul 07; 319(1):51-3.N Engl J Med1988-07-07T00:00:001988Granulocyte-macrophage colony-stimulating factor and myelodysplastic syndromes.7662957Vadhan-Raj S, Broxmeyer HE, Andreeff M, Bandres JC, Buescher ES, Benjamin RS, Papadopoulos NE, Burgess A, Patel S, Plager C, Hittelman WN, McAlister I, Garrison L, Williams DEBloodIn vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood. 1995 Sep 15; 86(6):2098-105.Blood1995-09-15T00:00:001995In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study.8151314Vadhan-Raj S, Kudelka AP, Garrison L, Gano J, Edwards CL, Freedman RS, Kavanagh JJJournal of clinical oncology : official journal of the American Society of Clinical OncologyEffects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol. 1994 Apr; 12(4):707-14.J Clin Oncol1994-04-01T00:00:001994Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer.8268354Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj SClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaRole of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis. 1993 Oct; 17(4):705-7.Clin Infect Dis1993-10-01T00:00:001993Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer.8391053Hamilton RF, Vadhan-Raj S, Uthman M, Grey M, Holian AJournal of leukocyte biologyThe in vivo effects of PIXY321 therapy on human monocyte activity. J Leukoc Biol. 1993 Jun; 53(6):640-50.J Leukoc Biol1993-06-01T00:00:001993The in vivo effects of PIXY321 therapy on human monocyte activity.8396850Perkins RC, Vadhan-Raj S, Scheule RK, Hamilton R, Holian AAmerican journal of hematologyEffects of continuous high dose rhGM-CSF infusion on human monocyte activity. Am J Hematol. 1993 Aug; 43(4):279-85.Am J Hematol1993-08-01T00:00:001993Effects of continuous high dose rhGM-CSF infusion on human monocyte activity.8911126Verschraegen CF, Kudelka AP, Termrungruanglert W, de Leon CG, Edwards CL, Freedman RS, Kavanagh JJ, Vadhan-Raj SEuropean journal of cancer (Oxford, England : 1990)Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease. Eur J Cancer. 1996 Aug; 32A(9):1609-11.Eur J Cancer1996-08-01T00:00:001996Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease.9060566Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj SJournal of clinical oncology : official journal of the American Society of Clinical OncologyImpact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997 Mar; 15(3):1218-34.J Clin Oncol1997-03-01T00:00:001997Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.9101417Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj SJournal of immunotherapy (Hagerstown, Md. : 1997)Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study. J Immunother. 1997 Jan; 20(1):79-87.J Immunother1997-01-01T00:00:001997Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study.9626808Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, Benjamin RSAmerican journal of clinical oncologyResults of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998 Jun; 21(3):317-21.Am J Clin Oncol1998-06-01T00:00:001998Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas.9877247Benjapibal M, Kudelka AP, Vasuratna A, Edwards CL, Verschraegen CF, Valero V, Vadhan-Raj S, Kavanagh JJAnti-cancer drugsDocetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer. Anticancer Drugs. 1998 Jul; 9(6):577-9.Anticancer Drugs1998-07-01T00:00:001998Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer.11012192Jones DV, Ashby M, Vadhan-Raj S, Somlo G, Champlin R, Gajewski J, Hellmann S, Fyfe GStem cells (Dayton, Ohio)Recombinant human thrombopoietin clinical development. Stem Cells. 1998; 16 Suppl 2:199-206.Stem Cells1998-01-01T00:00:001998Recombinant human thrombopoietin clinical development.12115358Elting LS, Martin CG, Kurtin DJ, Cantor SB, Rubenstein EB, Rodriguez S, Kanesan K, Vadhan-Raj S, Benjamin RSCancerThe Bleeding Risk Index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors. Cancer. 2002 Jun 15; 94(12):3252-62.Cancer2002-06-15T00:00:002002The Bleeding Risk Index: a clinical prediction rule to guide the prophylactic use of platelet transfusions in patients with lymphoma or solid tumors.15720963Vadhan-Raj S, Cohen V, Bueso-Ramos CCurrent hematology reportsThrombopoietic growth factors and cytokines. Curr Hematol Rep. 2005 Mar; 4(2):137-44.Curr Hematol Rep2005-03-01T00:00:002005Thrombopoietic growth factors and cytokines.16575720Chaves J, Huen A, Bueso-Ramos C, Safdar A, Vadhan-Raj SClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaAerosolized ribavirin-induced reversible hepatotoxicity in a hematopoietic stem cell transplant recipient with Hodgkin lymphoma. Clin Infect Dis. 2006 Apr 15; 42(8):e72-5.Clin Infect Dis2006-03-13T00:00:002006Aerosolized ribavirin-induced reversible hepatotoxicity in a hematopoietic stem cell transplant recipient with Hodgkin lymphoma.1671002620030125 Study Group Trial, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi GJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol. 2006 May 20; 24(15):2290-7.J Clin Oncol2006-05-20T00:00:002006Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.17011451Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris J, Vadhan-Raj S, Hamilton SR, Lin EHInternational journal of radiation oncology, biology, physicsPhase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Nov 01; 66(3):762-71.Int J Radiat Oncol Biol Phys2006-11-01T00:00:002006Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.23983177Vadhan-Raj S, Strauss W, Ford D, Bernard K, Boccia R, Li J, Allen LFAmerican journal of hematologyEfficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol. 2014 Jan; 89(1):7-12.Am J Hematol2013-09-30T00:00:002013Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron.Gynecological Oncology & Reproductive MedicineHematopathologyLeukemiaLymphoma-MyelomaPalliative Care & Rehabilitation MedicineSarcoma Medical OncologyMD AndersonRASHMIKANAGAL SHAMANNARASHMI KANAGAL SHAMANNA9653KANAGAL SHAMANNA, RASHMIAssistant Professor2.532890.0017706510research areas1.784760.0060279174coauthor of104.51811.577460similar to11148selected publicationsHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorEDUARDOBRUERAEDUARDO BRUERA8804BRUERA, EDUARDOProfessorROBERTCOLEMANROBERT COLEMAN9184COLEMAN, ROBERTProfessorCARLOS EBUESO-RAMOSCARLOS E BUESO-RAMOS8487BUESO-RAMOS, CARLOS EProfessorSHREYASKUMARPATELSHREYASKUMAR PATEL8514PATEL, SHREYASKUMARProfessorFREDRICK BHAGEMEISTERFREDRICK B HAGEMEISTER8570HAGEMEISTER, FREDRICK BProfessorL JEFFREYMEDEIROSL JEFFREY MEDEIROS8762MEDEIROS, L JEFFREYProfessorSRDANVERSTOVSEKSRDAN VERSTOVSEK8781VERSTOVSEK, SRDANProfessorGUILLERMOGARCIA-MANEROGUILLERMO GARCIA-MANERO8853GARCIA-MANERO, GUILLERMOProfessorAuthorship 2120361Authorship 2123924Authorship 2127414Authorship 2127926Authorship 2128141Authorship 2128611Authorship 2128951Authorship 2131026Authorship 2136435Authorship 2138363Authorship 2147752Authorship 2149146Authorship 2153256Authorship 2155021Authorship 2157668Authorship 2158031Authorship 2159091Authorship 2161353Authorship 2180882Authorship 2183551Authorship 2184741Authorship 2189171Authorship 2195211Authorship 2203781Authorship 220597Authorship 2230586Authorship 22391115Authorship 2252815Authorship 2255841Authorship 2255972Authorship 22653722Authorship 2271052Authorship 2273463Authorship 2279701Authorship 2299491Authorship 2323123Authorship 23256111492234Vadhan-Raj S, Broxmeyer HE, Hittelman WNSeminars in hematologyUse of granulocyte-macrophage colony-stimulating factor in hematopoietic disorders: biology and nature of response. Semin Hematol. 1992 Oct; 29(4 Suppl 3):4-13.Semin Hematol1992-10-01T00:00:001992Use of granulocyte-macrophage colony-stimulating factor in hematopoietic disorders: biology and nature of response.2202475Hittelman WN, Tigaud JD, Estey E, Vadhan-Raj SBone marrow transplantationPremature chromosome condensation in the study of minimal residual disease. Bone Marrow Transplant. 1990 Jul; 6 Suppl 1:9-13.Bone Marrow Transplant1990-07-01T00:00:001990Premature chromosome condensation in the study of minimal residual disease.2405649Vadhan-Raj S, Velasquez WS, Butler JJ, LeMaistre A, Lepe-Zuniga J, Keating MJ, Koller CA, Gutterman JUAmerican journal of hematologyStimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte-macrophage colony-stimulating factor. Am J Hematol. 1990 Mar; 33(3):189-97.Am J Hematol1990-03-01T00:00:001990Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte-macrophage colony-stimulating factor.2653858Broxmeyer HE, Cooper S, Vadhan-Raj SExperimental hematologyCell cycle status of erythroid (BFU-E) progenitor cells from the bone marrows of patients on a clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1989 Jun; 17(5):455-9.Exp Hematol1989-06-01T00:00:001989Cell cycle status of erythroid (BFU-E) progenitor cells from the bone marrows of patients on a clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor.3259659Ince C, Blick M, Lee M, Pathak S, Vadhan-Raj S, Selvanayagam P, Gutterman JU, Cabanillas FLeukemiaBcl-1 gene rearrangements in B cell lymphoma. Leukemia. 1988 Jun; 2(6):343-6.Leukemia1988-06-01T00:00:001988Bcl-1 gene rearrangements in B cell lymphoma.3260558Broxmeyer HE, Cooper S, Williams DE, Hangoc G, Gutterman JU, Vadhan-Raj SExperimental hematologyGrowth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1988 Aug; 16(7):594-602.Exp Hematol1988-08-01T00:00:001988Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor.3291976Vadhan-Raj S, Buescher S, LeMaistre A, Keating M, Walters R, Ventura C, Hittelman W, Broxmeyer HE, Gutterman JUBloodStimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1988 Jul; 72(1):134-41.Blood1988-07-01T00:00:001988Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor.3500414Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JUThe New England journal of medicineEffects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987 Dec 17; 317(25):1545-52.N Engl J Med1987-12-17T00:00:001987Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.3883355Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJProceedings of the National Academy of Sciences of the United States of AmericaMouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A. 1985 Feb; 82(4):1242-6.Proc Natl Acad Sci U S A1985-02-01T00:00:001985Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.3936042Nathan CF, Horowitz CR, de la Harpe J, Vadhan-Raj S, Sherwin SA, Oettgen HF, Krown SEProceedings of the National Academy of Sciences of the United States of AmericaAdministration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci U S A. 1985 Dec; 82(24):8686-90.Proc Natl Acad Sci U S A1985-12-01T00:00:001985Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide.7895781Broxmeyer HE, Benninger L, Cooper S, Hague N, Benjamin RS, Vadhan-Raj SExperimental hematologyEffects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma. Exp Hematol. 1995 Apr; 23(4):335-40.Exp Hematol1995-04-01T00:00:001995Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.8151315Vadhan-Raj S, Papadopoulos NE, Burgess MA, Linke KA, Patel SR, Hays C, Arcenas A, Plager C, Kudelka AP, Hittelman WNJournal of clinical oncology : official journal of the American Society of Clinical OncologyEffects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol. 1994 Apr; 12(4):715-24.J Clin Oncol1994-04-01T00:00:001994Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.8195637Moore DF, Buescher S, Vadhan-Raj SThe Journal of infectious diseasesInterleukin-1 alpha administration increases oral granulocytes and epithelial cells. J Infect Dis. 1994 Jun; 169(6):1419-20.J Infect Dis1994-06-01T00:00:001994Interleukin-1 alpha administration increases oral granulocytes and epithelial cells.8513450Buescher ES, McIlheran SM, Banks SM, Kudelka AP, Kavanagh JJ, Vadhan-Raj SCancer immunology, immunotherapy : CIIThe effects of interleukin-1 therapy on peripheral blood granulocyte function in humans. Cancer Immunol Immunother. 1993 Jul; 37(1):26-30.Cancer Immunol Immunother1993-07-01T00:00:001993The effects of interleukin-1 therapy on peripheral blood granulocyte function in humans.8714611Vadhan-Raj SSeminars in hematologyRecombinant human erythropoietin in combination with other hematopoietic cytokines in attenuating chemotherapy-induced multilineage myelosuppression: brief communication. Semin Hematol. 1996 Jan; 33(1 Suppl 1):16-8.Semin Hematol1996-01-01T00:00:001996Recombinant human erythropoietin in combination with other hematopoietic cytokines in attenuating chemotherapy-induced multilineage myelosuppression: brief communication.8724699Ritchie A, Vadhan-Raj S, Broxmeyer HEStem cells (Dayton, Ohio)Thrombopoietin suppresses apoptosis and behaves as a survival factor for the human growth factor-dependent cell line, M07e. Stem Cells. 1996 May; 14(3):330-6.Stem Cells1996-05-01T00:00:001996Thrombopoietin suppresses apoptosis and behaves as a survival factor for the human growth factor-dependent cell line, M07e.9502616Murray LJ, Luens KM, Estrada MF, Bruno E, Hoffman R, Cohen RL, Ashby MA, Vadhan-Raj SExperimental hematologyThrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis. Exp Hematol. 1998 Mar; 26(3):207-16.Exp Hematol1998-03-01T00:00:001998Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis.9834938Prow D, Vadhan-Raj SOncology (Williston Park, N.Y.)Thrombopoietin: biology and potential clinical applications. Oncology (Williston Park). 1998 Nov; 12(11):1597-604, 1607-8; discussion 1611-4.Oncology (Williston Park)1998-11-01T00:00:001998Thrombopoietin: biology and potential clinical applications.10050726Vadhan-Raj S, Currie LM, Bueso-Ramos C, Livesey SA, Connor JBritish journal of haematologyEnhanced retention of in vitro functional activity of platelets from recombinant human thrombopoietin-treated patients following long-term cryopreservation with a platelet-preserving solution (ThromboSol) and 2% DMSO. Br J Haematol. 1999 Feb; 104(2):403-11.Br J Haematol1999-02-01T00:00:001999Enhanced retention of in vitro functional activity of platelets from recombinant human thrombopoietin-treated patients following long-term cryopreservation with a platelet-preserving solution (ThromboSol) and 2% DMSO.10691586Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelk? AP, Freedman RS, Edwards CL, Gershenson D, Jones D, Ashby M, Kavanagh JJAnnals of internal medicineRecombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000 Mar 07; 132(5):364-8.Ann Intern Med2000-03-07T00:00:002000Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.10831286Vadhan-Raj SSeminars in hematologyClinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Semin Hematol. 2000 Apr; 37(2 Suppl 4):28-34.Semin Hematol2000-04-01T00:00:002000Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia.11497230Vadhan-Raj SOncology (Williston Park, N.Y.)Recombinant human thrombopoietin in myelosuppressive chemotherapy. Oncology (Williston Park). 2001 Jul; 15(7 Suppl 8):35-8.Oncology (Williston Park)2001-07-01T00:00:002001Recombinant human thrombopoietin in myelosuppressive chemotherapy.12090979Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos C, Verschraegen CF, Narvios AB, Connor J, Hoots WK, Broemeling LD, Lichtiger BLancet (London, England)Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet. 2002 Jun 22; 359(9324):2145-52.Lancet2002-06-22T00:00:002002Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.12493312Wautier JLLancet (London, England)Safety and usefulness of autologous cryopreserved platelets. Lancet. 2002 Dec 14; 360(9349):1985.Lancet2002-12-14T00:00:002002Safety and usefulness of autologous cryopreserved platelets.15070700Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BBBloodNuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004 Apr 15; 103(8):3175-84.Blood2003-12-18T00:00:002003Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.16038645Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, Lyman GH, Michaud L, Motl S, Vadhan-Raj S, Wong MK, National Comprehensive Cancer NetworkJournal of the National Comprehensive Cancer Network : JNCCNMyeloid growth factors clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jul; 3(4):540-55.J Natl Compr Canc Netw2005-07-01T00:00:002005Myeloid growth factors clinical practice guidelines in oncology.16636680Merzianu M, Jiang L, Lin P, Wang X, Weber DM, Vadhan-Raj S, Nguyen MH, Medeiros LJ, Bueso-Ramos CEModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncNuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenstr?m macroglobulinemia and does not correlate with p65 NF-kappaB activation. Mod Pathol. 2006 Jul; 19(7):891-8.Mod Pathol2006-04-21T00:00:002006Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenstr?m macroglobulinemia and does not correlate with p65 NF-kappaB activation.18642348Cella D, Viswanathan HN, Hays RD, Mendoza TR, Stein KD, Pasta DJ, Foreman AJ, Vadhan-Raj S, Kallich JDCancerDevelopment of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. Cancer. 2008 Sep 15; 113(6):1480-8.Cancer2008-09-15T00:00:002008Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy.19176207Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK, National Comprehensive Cancer NetworkJournal of the National Comprehensive Cancer Network : JNCCNMyeloid growth factors. J Natl Compr Canc Netw. 2009 Jan; 7(1):64-83.J Natl Compr Canc Netw2009-01-01T00:00:002009Myeloid growth factors.19231100Park HC, Janjan NA, Mendoza TR, Lin EH, Vadhan-Raj S, Hundal M, Zhang Y, Delclos ME, Crane CH, Das P, Wang XS, Cleeland CS, Krishnan SInternational journal of radiation oncology, biology, physicsTemporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2009 Nov 01; 75(3):775-81.Int J Radiat Oncol Biol Phys2009-02-21T00:00:002009Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer.19245931Vadhan-Raj SSeminars in hematologyManagement of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol. 2009 Jan; 46(1 Suppl 2):S26-32.Semin Hematol2009-01-01T00:00:002009Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.19264351Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RSGynecologic oncologyA phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009 May; 113(2):210-5.Gynecol Oncol2009-03-04T00:00:002009A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.19714603Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Vescio R, Smith J, Qian Y, Yeh H, Jun SAmerican journal of hematologyAn open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol. 2009 Oct; 84(10):650-6.Am J Hematol2009-10-01T00:00:002009An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma.20062013Liang M, Han X, Vadhan-Raj S, Nguyen M, Zhang YH, Fernandez M, Drakos E, Konoplev SN, Yin CC, Miranda RN, McDonnell TJ, Medeiros LJ, Bueso-Ramos CEModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncHDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis. Mod Pathol. 2010 Mar; 23(3):381-91.Mod Pathol2010-01-08T00:00:002010HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis.21159724Vadhan-Raj S, Zhou X, Sizer K, Lal L, Wang X, Roquemore J, Shi W, Benjamin RS, Lichtiger BThe oncologistImpact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions. Oncologist. 2010; 15(12):1359-69.Oncologist2010-12-15T00:00:002010Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions.22851406Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, Henry DH, Novello S, Hungria V, Qian Y, Feng A, Yeh H, Chung KAnnals of oncology : official journal of the European Society for Medical OncologyClinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol. 2012 Dec; 23(12):3045-3051.Ann Oncol2012-07-31T00:00:002012Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.23066397Kanagal-Shamanna R, Zhao W, Vadhan-Raj S, Nguyen MH, Fernandez MH, Medeiros LJ, Bueso-Ramos CEInternational journal of environmental research and public healthOver-expression of CYP2E1 mRNA and protein: implications of xenobiotic induced damage in patients with de novo acute myeloid leukemia with inv(16)(p13.1q22); CBF?-MYH11. Int J Environ Res Public Health. 2012 08; 9(8):2788-800.Int J Environ Res Public Health2012-08-03T00:00:002012Over-expression of CYP2E1 mRNA and protein: implications of xenobiotic induced damage in patients with de novo acute myeloid leukemia with inv(16)(p13.1q22); CBF?-MYH11.Authorship 2356402Authorship 2356978Authorship 2359454Authorship 2363451Authorship 2364672Authorship 2364691Authorship 2366423Authorship 2369173Authorship 2369181Authorship 2369921Authorship 2370642Authorship 2371191Authorship 2373931Authorship 2379631Authorship 2382852Authorship 238960Authorship 2389971Authorship 2391854Authorship 2396002Authorship 2403851Authorship 2431595Authorship 2441633Authorship 2446052Authorship 2453861Authorship 2479645Authorship 2488263Authorship 2530326Authorship 2538547Authorship 2539411Authorship 25583910Authorship 2559567Authorship 2575011Authorship 2583237Authorship 2594143Authorship 2614851Authorship 2622462Authorship 26259941697401Schilling PJ, Vadhan-Raj SThe New England journal of medicineConcurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia. N Engl J Med. 1990 Sep 20; 323(12):833-4.N Engl J Med1990-09-20T00:00:001990Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia.1726456Broxmeyer HE, Maze R, Miyazawa K, Carow C, Hendrie PC, Cooper S, Hangoc G, Vadhan-Raj S, Lu LCancer cells (Cold Spring Harbor, N.Y. : 1989)The kit receptor and its ligand, steel factor, as regulators of hemopoiesis. Cancer Cells. 1991 Dec; 3(12):480-7.Cancer Cells1991-12-01T00:00:001991The kit receptor and its ligand, steel factor, as regulators of hemopoiesis.2167293Buescher ES, McIlheran SM, Banks SM, Vadhan-Raj SInfection and immunityAlteration of the functional effects of granulocyte-macrophage colony-stimulating factor on polymorphonuclear leukocytes by membrane-fluidizing agents. Infect Immun. 1990 Sep; 58(9):3002-8.Infect Immun1990-09-01T00:00:001990Alteration of the functional effects of granulocyte-macrophage colony-stimulating factor on polymorphonuclear leukocytes by membrane-fluidizing agents.2183890Vadhan-Raj S, Hittelman WN, Lepe-Zuniga JL, Gutterman JU, Broxmeyer HEBloodRegulation of endogenous erythropoietin levels in anemia associated with myelodysplastic syndromes. Blood. 1990 Apr 15; 75(8):1749-50.Blood1990-04-15T00:00:001990Regulation of endogenous erythropoietin levels in anemia associated with myelodysplastic syndromes.2198660Gutterman J, Vadhan-Raj S, Logothetis C, Anaissle E, Estey E, Talpaz M, Kurzrock RSeminars in hematologyEffects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense. Semin Hematol. 1990 Jul; 27(3 Suppl 3):15-24.Semin Hematol1990-07-01T00:00:001990Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense.2201554Ventura GJ, Hester JP, Buescher ES, Vadhan-Raj S, Durrett A, Reading CLExperimental hematologyHematopoiesis in limiting dilution cultures: influence of cytokines on human hematopoietic progenitor cells. Exp Hematol. 1990 Sep; 18(8):878-82.Exp Hematol1990-09-01T00:00:001990Hematopoiesis in limiting dilution cultures: influence of cytokines on human hematopoietic progenitor cells.2457669Krown SE, Real FX, Vadhan-Raj S, Oettgen HFJournal of experimental pathologyInterferon in AIDS. J Exp Pathol. 1987; 3(4):681-91.J Exp Pathol1987-01-01T00:00:001987Interferon in AIDS.2676013Vadhan-Raj S, Broxmeyer HE, Spitzer G, LeMaistre A, Hultman S, Ventura G, Tigaud JD, Cork MA, Trujillo JM, Gutterman JUBloodStimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood. 1989 Oct; 74(5):1491-8.Blood1989-10-01T00:00:001989Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome.2687811Vadhan-Raj SOncology nursing forumClinical applications of colony-stimulating factors. Oncol Nurs Forum. 1989 Nov-Dec; 16(6 Suppl):21-6.Oncol Nurs Forum1989-11-01T00:00:001989Clinical applications of colony-stimulating factors.3053927Buescher ES, McIlheran SM, Vadhan-Raj SThe Journal of infectious diseasesEffects of in vivo administration of recombinant human granulocyte-macrophage colony-stimulating factor on human neutrophil chemotaxis and oxygen metabolism. J Infect Dis. 1988 Nov; 158(5):1140-2.J Infect Dis1988-11-01T00:00:001988Effects of in vivo administration of recombinant human granulocyte-macrophage colony-stimulating factor on human neutrophil chemotaxis and oxygen metabolism.3059191Vadhan-Raj S, Buescher S, Broxmeyer HE, LeMaistre A, Lepe-Zuniga JL, Ventura G, Jeha S, Horwitz LJ, Trujillo JM, Gillis SThe New England journal of medicineStimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1988 Dec 22; 319(25):1628-34.N Engl J Med1988-12-22T00:00:001988Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor.3080551Vadhan-Raj S, Al-Katib A, Bhalla R, Pelus L, Nathan CF, Sherwin SA, Oettgen HF, Krown SEJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol. 1986 Feb; 4(2):137-46.J Clin Oncol1986-02-01T00:00:001986Phase I trial of recombinant interferon gamma in cancer patients.3146907Broxmeyer HE, Vadhan-Raj S, Hangoc G, Lu L, Gutterman JU, Williams DEAdvances in experimental medicine and biologyPreclinical and clinical effects of the hematopoietic colony stimulating factors. Adv Exp Med Biol. 1988; 241:233-41.Adv Exp Med Biol1988-01-01T00:00:001988Preclinical and clinical effects of the hematopoietic colony stimulating factors.7510197Arcenas AG, Vadhan-Raj SLeukemia & lymphomaHematopoietic growth factor therapy of myelodysplastic syndromes. Leuk Lymphoma. 1993; 11 Suppl 2:65-9.Leuk Lymphoma1993-01-01T00:00:001993Hematopoietic growth factor therapy of myelodysplastic syndromes.7681784Maze R, Horie M, Hendrie P, Vadhan-Raj S, Tricot G, Gordon M, Nemunaitis J, Ashman LK, Broxmeyer HEExperimental hematologyDifferential responses of myeloid progenitor cells from patients with myeloid leukemia and myelodysplasia to the costimulating effects of steel factor in vitro. Exp Hematol. 1993 Apr; 21(4):545-51.Exp Hematol1993-04-01T00:00:001993Differential responses of myeloid progenitor cells from patients with myeloid leukemia and myelodysplasia to the costimulating effects of steel factor in vitro.8075592Vadhan-Raj SStem cells (Dayton, Ohio)PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development. Stem Cells. 1994 May; 12(3):253-61.Stem Cells1994-05-01T00:00:001994PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development.8405227Buescher ES, McIlheran SM, Banks SM, Vadhan-Raj SExperimental hematologyThe effects of treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on human polymorphonuclear leukocyte function. Exp Hematol. 1993 Oct; 21(11):1467-72.Exp Hematol1993-10-01T00:00:001993The effects of treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on human polymorphonuclear leukocyte function.8409753Lee AM, Vadhan-Raj S, Hamilton RF, Scheule RK, Holian AJournal of leukocyte biologyThe in vivo effects of rhIL-1 alpha therapy on human monocyte activity. J Leukoc Biol. 1993 Oct; 54(4):314-21.J Leukoc Biol1993-10-01T00:00:001993The in vivo effects of rhIL-1 alpha therapy on human monocyte activity.8656266Journal of clinical oncology : official journal of the American Society of Clinical OncologyUpdate of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1996 Jun; 14(6):1957-60.J Clin Oncol1996-06-01T00:00:001996Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.9139552Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, Johnston T, Papadopolous NE, Hittelman WN, Johnston DA, Yang TA, Paton VE, Cohen RL, Hellmann SD, Benjamin RS, Broxmeyer HEAnnals of internal medicineStimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997 May 01; 126(9):673-81.Ann Intern Med1997-05-01T00:00:001997Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.9196153Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RSJournal of clinical oncology : official journal of the American Society of Clinical OncologyHigh-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol. 1997 Jun; 15(6):2378-84.J Clin Oncol1997-06-01T00:00:001997High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.9685172Vadhan-Raj SSeminars in hematologyRecombinant human thrombopoietin: clinical experience and in vivo biology. Semin Hematol. 1998 Jul; 35(3):261-8.Semin Hematol1998-07-01T00:00:001998Recombinant human thrombopoietin: clinical experience and in vivo biology.11319596Grazziutti M, Przepiorka D, Rex JH, Braunschweig I, Vadhan-Raj S, Savary CABone marrow transplantationDendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Marrow Transplant. 2001 Mar; 27(6):647-52.Bone Marrow Transplant2001-03-01T00:00:002001Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus.12435171Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WPOncology (Williston Park, N.Y.)Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. Oncology (Williston Park). 2002 Oct; 16(10 Suppl 11):31-6.Oncology (Williston Park)2002-10-01T00:00:002002Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.12915607Vadhan-Raj S, Patel S, Bueso-Ramos C, Folloder J, Papadopolous N, Burgess A, Broemeling LD, Broxmeyer HE, Benjamin RSJournal of clinical oncology : official journal of the American Society of Clinical OncologyImportance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol. 2003 Aug 15; 21(16):3158-67.J Clin Oncol2003-08-15T00:00:002003Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia.14614003Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, Kavanagh JJ, Hicks ME, Levy LB, Folloder JK, Garcia MEClinical cancer research : an official journal of the American Association for Cancer ResearchPilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res. 2003 Nov 01; 9(14):5228-37.Clin Cancer Res2003-11-01T00:00:002003Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas.17063086Zhao W, Claxton DF, Medeiros LJ, Lu D, Vadhan-Raj S, Kantarjian HM, Nguyen MH, Bueso-Ramos CEThe American journal of surgical pathologyImmunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22). Am J Surg Pathol. 2006 Nov; 30(11):1436-44.Am J Surg Pathol2006-11-01T00:00:002006Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).17164350Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BBBloodResveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007 Mar 15; 109(6):2293-302.Blood2006-12-12T00:00:002006Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.19672946Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CECancerCuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer. 2009 Dec 01; 115(23):5481-9.Cancer2009-12-01T00:00:002009Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation.19795582Vadhan-Raj SJournal of the National Comprehensive Cancer Network : JNCCNFuture directions with hematopoietic growth factors. J Natl Compr Canc Netw. 2003 Jan; 1 Suppl 1:S96-101.J Natl Compr Canc Netw2003-01-01T00:00:002003Future directions with hematopoietic growth factors.20473273Kasyan A, Medeiros LJ, Zuo Z, Santos FP, Ravandi-Kashani F, Miranda R, Vadhan-Raj S, Koeppen H, Bueso-Ramos CEModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncAcute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod Pathol. 2010 Aug; 23(8):1113-26.Mod Pathol2010-05-14T00:00:002010Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease.21343556Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh HJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011 Mar 20; 29(9):1125-32.J Clin Oncol2011-02-22T00:00:002011Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.21654313Raj SD, Zhou X, Bueso-Ramos CE, Ravi V, Patel S, Benjamin RS, Vadhan-Raj SAmerican journal of clinical oncologyPrognostic significance of elevated D-dimer for survival in patients with sarcoma. Am J Clin Oncol. 2012 Oct; 35(5):462-7.Am J Clin Oncol2012-10-01T00:00:002012Prognostic significance of elevated D-dimer for survival in patients with sarcoma.22015451Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JEAnnals of oncology : official journal of the European Society for Medical OncologyA randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5.Ann Oncol2011-10-19T00:00:002011A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.22038701Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, Vadhan-Raj S, Hoehn D, Medeiros LJ, Yin CCCancerMyeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer. 2012 Jun 01; 118(11):2879-88.Cancer2011-10-28T00:00:002011Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.22042783Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GNThe oncologistPhase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34.Oncologist2011-10-31T00:00:002011Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.24251854Vadhan-Raj S, Goldberg JD, Perales MA, Berger DP, van den Brink MRJournal of cellular and molecular medicineClinical applications of palifermin: amelioration of oral mucositis and other potential indications. J Cell Mol Med. 2013 Nov; 17(11):1371-84.J Cell Mol Med2013-11-19T00:00:002013Clinical applications of palifermin: amelioration of oral mucositis and other potential indications.Authorship 2627211Authorship 2627568Authorship 2634435Authorship 26445914Authorship 2645002Authorship 2660101Authorship 26724322Authorship 2680458Authorship 2691205Authorship 2695891Authorship 27028114Authorship 27242711373894Broxmeyer HE, Hangoc G, Cooper S, Ribeiro RC, Graves V, Yoder M, Wagner J, Vadhan-Raj S, Benninger L, Rubinstein PProceedings of the National Academy of Sciences of the United States of AmericaGrowth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A. 1992 May 01; 89(9):4109-13.Proc Natl Acad Sci U S A1992-05-01T00:00:001992Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults.2405922Vadhan-Raj S, Jeha SS, Buescher S, LeMaistre A, Yee G, Lu L, Lloreta J, Hoots WK, Hittelman WN, Gutterman JUBloodStimulation of myelopoiesis in a patient with congenital neutropenia: biology and nature of response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1990 Feb 15; 75(4):858-64.Blood1990-02-15T00:00:001990Stimulation of myelopoiesis in a patient with congenital neutropenia: biology and nature of response to recombinant human granulocyte-macrophage colony-stimulating factor.7506671Broxmeyer HE, Benninger L, Patel SR, Benjamin RS, Vadhan-Raj SExperimental hematologyKinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1994 Jan; 22(1):100-2.Exp Hematol1994-01-01T00:00:001994Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor.7647956Vassilopoulou-Sellin R, Kudelka AP, Kavanagh JJ, Edwards CL, Vadhan-Raj SJournal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological TherapyEffects of interleukin-1 alpha administration on pituitary-adrenal and pituitary-thyroid axes function of patients with ovarian cancer. J Immunother Emphasis Tumor Immunol. 1995 Feb; 17(2):109-13.J Immunother Emphasis Tumor Immunol1995-02-01T00:00:001995Effects of interleukin-1 alpha administration on pituitary-adrenal and pituitary-thyroid axes function of patients with ovarian cancer.7778576Moore DF, Vadhan-Raj SThe American journal of medicineSustained response in Felty's syndrome to prolonged administration of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Am J Med. 1995 Jun; 98(6):591-4.Am J Med1995-06-01T00:00:001995Sustained response in Felty's syndrome to prolonged administration of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF).8811495Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, Rieger PT, Saleh M, Khazaeli MB, Vadhan-Raj SJournal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological TherapyPhase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1996 May; 19(3):206-17.J Immunother Emphasis Tumor Immunol1996-05-01T00:00:001996Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.15352656Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WPThe journal of supportive oncologyAssessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol. 2003 Jul-Aug; 1(2):131-8.J Support Oncol2003-07-01T00:00:002003Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.17335688Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Heaney ML, Htoy S, Kloth DD, Lyman GH, Messersmith WA, Michaud LB, Miyata SC, Robbins A, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK, National Comprehensive Cancer Network (NCCN)Journal of the National Comprehensive Cancer Network : JNCCNMyeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb; 5(2):188-202.J Natl Compr Canc Netw2007-02-01T00:00:002007Myeloid growth factors. Clinical practice guidelines in oncology.17571080Sun X, Zhang W, Ramdas L, Stivers DN, Jones DM, Kantarjian HM, Estey EH, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CEModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncComparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. Mod Pathol. 2007 Aug; 20(8):811-20.Mod Pathol2007-06-15T00:00:002007Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping.19669217Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CEJournal of hematopathologyAnalysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop. 2009 Mar; 2(1):2-8.J Hematop2008-11-04T00:00:002008Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.20620436Vadhan-Raj SSeminars in hematologyClinical findings with the first generation of thrombopoietic agents. Semin Hematol. 2010 Jul; 47(3):249-57.Semin Hematol2010-07-01T00:00:002010Clinical findings with the first generation of thrombopoietic agents.21900221Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M, National Comprehensive Cancer NetworkJournal of the National Comprehensive Cancer Network : JNCCNMyeloid growth factors. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):914-32.J Natl Compr Canc Netw2011-08-01T00:00:002011Myeloid growth factors.Authorship 2731888Authorship 2738608Authorship 27502419Authorship 2750342Authorship 2758011Authorship 2760657Authorship 2762104Authorship 27634210Authorship 2764572Authorship 2772697Authorship 27765962660675Vadhan-Raj S, Hittelman WN, Broxmeyer HE, Keating M, Urdal D, Gutterman JUAnnals of the New York Academy of SciencesIn vivo biologic activities of recombinant human granulocyte-macrophage colony-stimulating factor. Ann N Y Acad Sci. 1989; 554:231-40.Ann N Y Acad Sci1989-01-01T00:00:001989In vivo biologic activities of recombinant human granulocyte-macrophage colony-stimulating factor.7492626Broxmeyer HE, Cooper S, Hague N, Benninger L, Sarris A, Cornetta K, Vadhan-Raj S, Hendrie P, Mantel CAnnals of hematologyHuman chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice. Ann Hematol. 1995 Nov; 71(5):235-46.Ann Hematol1995-11-01T00:00:001995Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice.7872336Anaissie EJ, Vadhan-Raj SThe American journal of medicineIs it time to redefine the management of febrile neutropenia in cancer patients? Am J Med. 1995 Mar; 98(3):221-3.Am J Med1995-03-01T00:00:001995Is it time to redefine the management of febrile neutropenia in cancer patients?7875147Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj SEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical MicrobiologyRole of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis. 1994; 13 Suppl 2:S18-22.Eur J Clin Microbiol Infect Dis1994-01-01T00:00:001994Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection.9457817Glisson B, Komaki R, Lee JS, Shin DM, Fossella F, Murphy WK, Kurie J, Perez-Soler R, Schea R, Vadhan-Raj SInternational journal of radiation oncology, biology, physicsIntegration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):331-6.Int J Radiat Oncol Biol Phys1998-01-15T00:00:001998Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study.12627519Elting LS, Cantor SB, Martin CG, Hamblin L, Kurtin D, Rivera E, Vadhan-Raj S, Benjamin RSCancerCost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer. 2003 Mar 15; 97(6):1541-50.Cancer2003-03-15T00:00:002003Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors.14991544Bueso-Ramos CE, Rocha FC, Shishodia S, Medeiros LJ, Kantarjian HM, Vadhan-Raj S, Estrov Z, Smith TL, Nguyen MH, Aggarwal BBHuman pathologyExpression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol. 2004 Feb; 35(2):246-53.Hum Pathol2004-02-01T00:00:002004Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia.16979517Johnson MR, Del Carpio-Jayo D, Lin P, Giralt S, Anderlini P, Champlin RE, Khouri IF, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CEAnnals of diagnostic pathologyPrimary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Diagn Pathol. 2006 Oct; 10(5):263-8.Ann Diagn Pathol2006-10-01T00:00:002006Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation.20920696Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj SThe American journal of medicineIncidence and risk factors of venous thromboembolic events in lymphoma. Am J Med. 2010 Oct; 123(10):935-41.Am J Med2010-10-01T00:00:002010Incidence and risk factors of venous thromboembolic events in lymphoma.24142827Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M, National comprehensive cancer networkJournal of the National Comprehensive Cancer Network : JNCCNMyeloid growth factors. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1266-90.J Natl Compr Canc Netw2013-10-01T00:00:002013Myeloid growth factors.24162260Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh HSupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerDelaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014 Mar; 22(3):679-87.Support Care Cancer2013-10-26T00:00:002013Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.8991194Kudelka AP, Termrungruanglert W, Vadhan-Raj S, Edwards CL, Varma DG, Tornos C, Verschraegen CF, Kavanagh JJAnti-cancer drugsRemission of advanced uterine leiomyosarcoma with pulmonary metastases with carboplatin and paclitaxel. Anticancer Drugs. 1996 Nov; 7(8):885-9.Anticancer Drugs1996-11-01T00:00:001996Remission of advanced uterine leiomyosarcoma with pulmonary metastases with carboplatin and paclitaxel.74Professor10Assistant Professor20855800Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RSAnnals of internal medicineSingle-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med. 2010 Sep 21; 153(6):358-67.Ann Intern Med2010-09-21T00:00:002010Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.Authorship 841381Authorship 841699Authorship 846411Authorship 854120Authorship 855003Authorship 855428Authorship 856020Authorship 856104Authorship 856845Authorship 858093Authorship 858430Authorship 858449Authorship 861160Authorship 864673Authorship 865419Authorship 865764Authorship 867845Journal of Community and Supportive OncologyEffects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemia. Journal of Community and Supportive Oncology. 14:342-350.Effects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemiaEuropean Journal of Cancer Part AEffects of interleukin-la on ovarian carcinoma in patients with recurrent disease. European Journal of Cancer Part A. 32:1598-1602.Effects of interleukin-la on ovarian carcinoma in patients with recurrent diseaseJournal of Translational MedicineCytokines, GM-CSF and IFNγ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. Journal of Translational Medicine. 4.Cytokines, GM-CSF and IFNγ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatinCancer BulletinHematopoietic growth factors in chemotherapy-induced myelosuppression. Cancer Bulletin. 43:208-214.Hematopoietic growth factors in chemotherapy-induced myelosuppressionJournal of Supportive OncologyDevelopment of the Brief Functional Capacity Tool (BFCT). Journal of Supportive Oncology. 5:10-11.Development of the Brief Functional Capacity Tool (BFCT)BloodErratum. Blood. 122:1325-1326.ErratumBlood Cancer JournalEvaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer Journal. 6.Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trialAmerican Journal of HematologySafety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. American Journal of Hematology. 91:E3-E5.Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapyOncologyIntegrating prophylactic measures into practice guidelines. Oncology. 13:593-597.Integrating prophylactic measures into practice guidelinesMouse monoclonal antibody detecting G(D3) ganglioside. Mouse monoclonal antibody detecting G(D3) gangliosideBloodEvaluation of interleukin-11 (IL-11) in combination with G-CSF administered by different schedules in sarcoma patients receiving adriamycin and ifosfamide (AI) chemotherapy. Blood. 96.Evaluation of interleukin-11 (IL-11) in combination with G-CSF administered by different schedules in sarcoma patients receiving adriamycin and ifosfamide (AI) chemotherapyFORUM - Trends in Experimental and Clinical MedicinePIXY321 (GM-CSF/IL-3 fusion protein). FORUM - Trends in Experimental and Clinical Medicine. 5:110-118.PIXY321 (GM-CSF/IL-3 fusion protein)Journal of Clinical OncologyReply to S.M. Sorscher et al. Journal of Clinical Oncology. 29:2736-2737.Reply to S.M. Sorscher et alClinical Infectious DiseasesErratum. Clinical Infectious Diseases. 42:1510.ErratumPhenotypic changes induced by recombinant interferon-gamma (r-IFN-γ) therapy in a case of chronic lymphocytic leukemia (CLL). Phenotypic changes induced by recombinant interferon-gamma (r-IFN-γ) therapy in a case of chronic lymphocytic leukemia (CLL)Journal of Supportive OncologyExpansion of bone marrow progenitors and mobilization of multilineage progenitor cells associated with one-per-cycle administration of the long-acting growth factors pegfilgrastim and darbepoetin alfa with chemotherapy. Journal of Supportive Oncology. 3:22-23.Expansion of bone marrow progenitors and mobilization of multilineage progenitor cells associated with one-per-cycle administration of the long-acting growth factors pegfilgrastim and darbepoetin alfa with chemotherapyJournal of Supportive OncologyEfficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in non-Hodgkin's lymphoma. Journal of Supportive Oncology. 3:24-25.Efficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in non-Hodgkin's lymphomaD013921Disorders4108380.668879ThrombocytopeniaD003115Chemicals & Drugs27820.977431Colony-Stimulating FactorsAuthorship 9180021Authorship 922540528111717Fogelman DR, Morris J, Xiao L, Hassan M, Vadhan S, Overman M, Javle S, Shroff R, Varadhachary G, Wolff R, Vence L, Maitra A, Cleeland C, Wang XSSupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerA predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Cancer. 2017 06; 25(6):1809-1817.Support Care Cancer2017-01-22T00:00:002017A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients.28327200Vadhan-Raj S, Abonour R, Goldman JW, Smith DA, Slapak CA, Ilaria RL, Tiu RV, Wang X, Callies S, Cox J, Tuttle JL, Lau YK, Roeland EJJournal of hematology & oncologyA first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 03 21; 10(1):73.J Hematol Oncol2017-03-21T00:00:002017A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.D006133Chemicals & DrugsPhysiology1603010.908434Growth SubstancesD016178Chemicals & Drugs1654090.861054Granulocyte-Macrophage Colony-Stimulating FactorD013926Chemicals & Drugs35770.953089Thrombopoietin16755175Lin EH, Curley SA, Crane CC, Feig B, Skibber J, Delcos M, Vadhan SR, Morris J, Ayers GD, Ross A, Brown T, Rodriguez-Bigas MA, Janjan NAmerican journal of clinical oncologyRetrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? Am J Clin Oncol. 2006 Jun; 29(3):232-9.Am J Clin Oncol2006-06-01T00:00:002006Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessor